CD19 and neoplasm: To allow for an analysis of the different B cell subpopulations within individual tumor samples, we included only tumor samples in which we could detect at least 50 B cells per mm2 by CD19 and/or CD20 immunoreactivity (36 primary melanomas, 23 melanoma metastases) in this comparison.